ABSTRACT
Objective: COVID-19 disease has affected all segments of society, especially healthcare workers. We aimed to evaluate the exercise capacity and cardiac functions of healthcare workers who had COVID-19 infection. Methods: Forty healthcare workers with COVID-19 infection (21 females, 19 males), who have completed their treatment, were assessed on the 30th day of recovery. Twenty healthy volunteers were matched as a control group. Exercise capacity was measured using the sixminute walk test (6MWT). The results of 6MWT were given as an absolute value in meters. Cardiac functions were evaluated by echocardiography. Results: Walking distances were similar in both healthcare workers with COVID-19 and healthy controls. 0´ pulse and 6´ pulse were significantly high in healthcare workers, whereas 0´ SpO2 was low in 6MWT. The thorax CT findings showed a positive correlation with the total number of symptoms and clinical severity. Ejection fraction (EF) showed a negative correlation with 6´ pulse, and the right atrial area revealed a negative correlation with 6´ SO2. The mean distance in 6MWT performed by inpatients and outpatients was 546.9±36.8 m vs 511.8±54.0 m, respectively. The walking distance and EF of outpatients were lower than inpatients. Enoxaparin treatment was independently associated with walking distance and EF. Conclusion: COVID-19 infection and hospitalization status affect cardiac functions and physical functional capacity. In our study, we showed that prophylactic enoxaparin use was the strongest independent factor affecting EF and walking distance in healthcare workers with mild to moderate COVID-19 infection. We think that it is important to follow up with healthcare professionals in terms of possible impairments in cardiac function and exercise capacity after COVID-19 infection. (English) [ FROM AUTHOR] Amaç: COVID-19 enfeksiyonu, başta sağlık çalışanları olmak üzere toplumun tüm kesimlerini etkilemiştir. COVID-19 enfeksiyonu olan sağlık çalışanlarının egzersiz kapasitesini ve kalp fonksiyonlarını değerlendirmeyi amaçladık. Gereç ve Yöntem: COVID-19 enfeksiyonlu (21 kadın, 19 erkek) tedavilerini tamamlayan 40 sağlık çalışanı, iyileşmelerinin otuzuncu gününde değerlendirildi. Yirmi sağlıklı gönüllü kontrol grubu olarak eşleştirildi. Egzersiz kapasitesi altı dakika yürüme testi (6DYT) ile ölçüldü. 6DYT sonuçları metre cinsinden mutlak değer olarak verildi. Kalp fonksiyonları ekokardiyografi ile değerlendirildi. Bulgular: COVID-19 enfeksiyonu geçirmiş sağlık çalışanları ve sağlıklı kontrollerde yürüme mesafesi benzerdi. Sağlık çalışanlarında 0' nabız ve 6' nabız anlamlı olarak yüksek, 6DYT'de 0' SpO2 düşüktü. Toraks BT bulguları, toplam semptom sayısı ve klinik şiddet ile pozitif korelasyon gösterdi. Ejeksiyon fraksiyonu (EF) 6' nabız ile negatif korelasyon ve RA alanı 6' SO2 ile negatif korelasyon bulundu. Yatan hastalar ve ayaktan hastalar tarafından yapılan 6DYT'de ortalama mesafe sırasıyla 546.9±36.8m ve 511.8±54.0m idi. Ayaktan hastaların yürüme mesafesi ve EF'si yatan hastalara göre daha düşüktü. Enoksaparin tedavisi bağımsız olarak yürüme mesafesi ve EF ile ilişkiliydi. Sonuç: COVID-19 enfeksiyonu ve hastanede yatış durumu, kardiyak fonksiyonları ve fiziksel fonksiyonel kapasiteyi etkilemektedir. Çalışmamızda, hafif ve orta dereceli COVID-19 enfeksiyonu geçirmiş sağlık çalışanlarında, EF ve yürüme mesafesini etkileyen en güçlü bağımsız faktörün profilaktik enoksaparin kullanımı olduğunu gösterdik. Sağlık çalışanlarının COVID-19 enfeksiyonu sonrası kardiyak fonksiyon ve egzersiz kapasitesinde olası sorunlar açısından takibinin önemli olduğu düşünmekteyiz. (Turkish) [ FROM AUTHOR] Copyright of Southern Clinics of Istanbul Eurasia is the property of KARE Publishing and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
OBJECTIVE: To assess and identify the risk of prolonged QT about hydroxychloroquine (HQ) and azithromycin (AZ) used in the treatment of patients with COVID-19. STUDY DESIGN: Cohort study. PLACE AND DURATION OF STUDY: Kartal Dr. Lütfi Kirdar City Hospital, Istanbul, Turkey, from March to May 2020. METHODOLOGY: One hundred and forty-four patients with the diagnosis of COVID-19, confirmed by Rt-PCR (reverse transcription-polymerase chain reaction), were restrospectively reviewed. Patients who were hospitalised, received HQ or HQ plus AZ treatment, had a baseline electrocardiogram (ECG), and had at least one ECG after treatment were included in the study. Patients with missing data were excluded. RESULTS: Fifty-one (35.4%) patients were given hydroxychloroquine monoterapy (HQ), 93 (64.6%) were given hydroxychloroquine plus azithromycin (HA), and 70 (48.6%) were women. Pre-treatment mean QTc measurements were calculated as 410.61 ± 29.44 milliseconds (ms) for HQ group and 412.02 ± 25.37 ms for HA group, while the mean values of post-treatment QTc measurements were calculated as 432.31 ± 33.97 ms for HQ group and 432.03 ± 27.0 ms for the HA group. Post-treatment QTc measurements of both HA group and HQ group were prolonged compared to pre-treatment measurements. Ventricular arrhythmia was not observed in any patient. CONCLUSION: For COVID-19, no globally accepted definite treatment has yet been found. Both of hydroxychloroquine monotherapy and hydroxychloroquine plus azithromycin treatment regimens cause QTc measurement to increase at a statistically significant level. We concluded that this increase in QTc did not cause ventricular arrhythmia. Key Words: COVID-19, QTc interval, Hydroxychloroquine, Azithromycin.